Pacer Advisors Inc. Sells 9,865 Shares of Moderna, Inc. $MRNA

Pacer Advisors Inc. cut its position in Moderna, Inc. (NASDAQ:MRNA) by 36.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 17,381 shares of the company’s stock after selling 9,865 shares during the quarter. Pacer Advisors Inc.’s holdings in Moderna were worth $883,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. MUFG Securities EMEA plc bought a new stake in shares of Moderna during the second quarter valued at approximately $28,000. Flagship Harbor Advisors LLC bought a new position in Moderna in the 4th quarter valued at approximately $31,000. Canton Hathaway LLC bought a new stake in shares of Moderna in the 1st quarter worth $31,000. EverSource Wealth Advisors LLC increased its holdings in shares of Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the transaction, the director directly owned 3,924 shares in the company, valued at approximately $183,800.16. The trade was a 70.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 119,406 shares of company stock valued at $5,928,762. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on MRNA shares. The Goldman Sachs Group upped their price target on Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a report on Tuesday, July 21st. Piper Sandler reissued an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Bank of America upped their target price on shares of Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Citigroup raised their price target on shares of Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Finally, UBS Group reiterated an “overweight” rating on shares of Moderna in a research note on Monday, August 3rd. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and five have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $42.13.

Moderna Stock Performance

MRNA stock opened at $59.17 on Monday. The company has a market cap of $23.62 billion, a P/E ratio of -7.41 and a beta of 0.91. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $85.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The stock’s fifty day moving average price is $60.28 and its 200-day moving average price is $53.20.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the prior year, the business earned ($2.13) earnings per share. Moderna’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities analysts forecast that Moderna, Inc. will post -6.2 earnings per share for the current year.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved mFLUSIVA, Moderna’s mRNA-based seasonal influenza vaccine, for adults ages 50 and older. It is the first mRNA flu vaccine approved in the United States and Moderna’s fourth FDA-approved product, supporting the company’s effort to diversify beyond COVID-19. The company expects limited retail availability in the coming weeks. US FDA approves first mRNA flu shot from Moderna
• Positive Sentiment: On its second-quarter earnings call, Moderna maintained its 2026 growth target while lowering cost guidance. The combination of preserved revenue expectations and lower spending could improve cash runway and reduce concerns about the company’s post-pandemic revenue decline. Management also highlighted upcoming milestones for flu, oncology and rare-disease programs. Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
• Positive Sentiment: Moderna began a Phase 1 Canadian trial of an investigational mRNA vaccine for Bundibugyo ebolavirus, a strain without an approved vaccine. Although early-stage, the program reinforces the breadth of Moderna’s infectious-disease platform and its partnerships with CEPI and Canadian public-health authorities. Moderna Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine
• Neutral Sentiment: The flu approval is a meaningful commercial opportunity, but Moderna still needs CDC recommendations, distribution and physician adoption to translate the regulatory win into material revenue. The initial authorization is limited to adults 50 and older, with established flu vaccines already competing for the upcoming season. Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain
• Negative Sentiment: Investors continue to face substantial execution risk: COVID-related revenue has fallen sharply from pandemic highs, Moderna remains loss-making, and future valuation depends heavily on successful Phase 3 oncology results and broader pipeline commercialization. Some brokerages maintain a “Reduce” view, limiting the immediate impact of the positive headlines.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.